Formulation development and systematic optimization of stabilized ziprasidone hydrochloride capsules devoid of any food effect

References

• Kraan T, Velthorst E, Smit F, et al. Trauma and recent life events in individuals at ultra high risk for psychosis: review and meta-analysis. Schizophr Res 2015;161:143–149
   PubMed Web of Science ®Google Scholar
• Mancuso SG, Morgan VA, Mitchell PB, et al. A comparison of schizophrenia, schizoaffective disorder, and bipolar disorder: results from the Second Australian national psychosis survey. J Affect Disord 2014;172C:30–37
   Google Scholar
• Hodgson KJ, Shelton KH, van den Bree MB. Mental health problems in young people with experiences of homelessness and the relationship with health service use: a follow-up study. Evid Based Ment Health 2014;17:76–80
   PubMedGoogle Scholar
• Mandrioli R, Protti M, Mercolini L. Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder. Expert Opin Drug Metab Toxicol 2015;11:149–174
   PubMed Web of Science ®Google Scholar
• Poo SX, Agius M. Atypical anti-psychotics in adult bipolar disorder: current evidence and updates in the NICE guidelines. Psychiatr Danub 2014;26:322–329
   PubMedGoogle Scholar
• Nielsen RE, Levander S, Kjaersdam Telleus G, et al. Second-generation antipsychotic effect on cognition in patients with schizophrenia – a meta-analysis of randomized clinical trials. Acta Psychiatr Scand 2015;131:185–196
   PubMed Web of Science ®Google Scholar
• Jung WY, Kim SG, Lee JS, et al. Open prospective study of ziprasidone in patients with schizophrenia with depressive symptoms: a multicenter study. Psychiatry Clin Neurosci 2015;69:43–48
   PubMed Web of Science ®Google Scholar
• Fasano CJ, O'Malley GF, Lares C, Rowden AK. Pediatric ziprasidone overdose. Pediatr Emerg Care 2009;25:258–259
   PubMed Web of Science ®Google Scholar
• Miao Y, Chen G, Ren L, Pingkai O. Characterization and evaluation of self-nanoemulsifying sustained-release pellet formulation of ziprasidone with enhanced bioavailability and no food effect. Drug Deliv 2014. [Epub ahead of print]. doi: 10.3109/10717544.2014.950768
   Google Scholar
• Yanfei M, Guoguang C, Lili R, Pingkai O. Controlled release of ziprasidone solid dispersion systems from osmotic pump tablets with enhanced bioavailability in the fasted state. Drug Dev Ind Pharm 2014. [Epub ahead of print]. doi: 10.3109/03639045.2014.950273
   PubMed Web of Science ®Google Scholar
• Thombre AG, Shah JC, Sagawa K, Caldwell WB. In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations. Int J Pharm 2012;428:8–17
   PubMed Web of Science ®Google Scholar
• Arenson DR, Busch FR, Hausberger AG, Rasadi B. Crystalline ziprasidone free base or crystalline ziprasidone hydrochloride particles with specific particle size are useful as antipsychosis agent. US Patent 6150366A 2000;21 Nov 2000
   Google Scholar
• Busch FR, Rose CA. Mesylatetrihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist. WO/1997/0421901997.13.11.1997
   Google Scholar
• Dong J, Song X, Lian X, et al. Subcutaneously injected ivermectin-loaded mixed micelles: formulation, pharmacokinetics and local irritation study. Drug Deliv 2014. [Epub ahead of print]. doi: 10.3109/10717544.2014.956849
   Google Scholar
• Yang L, Shao Y, Han HK. Improved pH-dependent drug release and oral exposure of telmisartan, a poorly soluble drug through the formation of drug-aminoclay complex. Int J Pharm 2014;471:258–263
   PubMed Web of Science ®Google Scholar
• Poorghorban M, Das U, Alaidi O, et al. Characterization of the host–guest complex of a curcumin analog with beta-cyclodextrin and beta-cyclodextrin-gemini surfactant and evaluation of its anticancer activity. Int J Nanomedicine 2015;10:503–515
   PubMed Web of Science ®Google Scholar
• Pradines B, Gallard JF, Iorga BI, et al. The unexpected increase of clotrimazole apparent solubility using randomly methylated beta-cyclodextrin. J Mol Recognit 2015;28:96–102
   PubMed Web of Science ®Google Scholar
• Ai F, Ma Y, Wang J, Li Y. Preparation, physicochemical characterization and in vitro dissolution studies of diosmin–cyclodextrin inclusion complexes. Iran J Pharm Res 2014;13:1115–1123
   PubMed Web of Science ®Google Scholar
• Yousaf AM, Kim DW, Oh YK, et al. Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation. Int J Nanomedicine 2015;10:1819–1830
   PubMed Web of Science ®Google Scholar
• Desai C, Prabhakar B. Development and evaluation of orally disintegrating tablets of cilostazol-beta-cyclodextrin inclusion complexes. Drug Dev Ind Pharm 2014. [Epub ahead of print]. doi: 10.3109/03639045.2014.972413
   Web of Science ®Google Scholar
• Pandey MM, Jaipal A, Charde SY, et al. Dissolution enhancement of felodipine by amorphous nanodispersions using an amphiphilic polymer: insight into the role of drug–polymer interactions on drug dissolution. Pharm Dev Technol 2015. [Epub ahead of print]. doi: 10.3109/10837450.2015.1022785
   Web of Science ®Google Scholar
• Kim NA, Choi du H, Lim JY, et al. Investigation of polymeric excipients for dutasteride solid dispersion and its physicochemical characterization. Arch Pharm Res 2014;37:214–224
   PubMed Web of Science ®Google Scholar
• Song WH, Park JH, Yeom DW, et al. Enhanced dissolution of celecoxib by supersaturating self-emulsifying drug delivery system (S-SEDDS) formulation. Arch Pharm Res 2013;36:69–78
   PubMed Web of Science ®Google Scholar
• Marghade S, Musmade PB, Moorkoth S. High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. J Chromatogr Sci 2012;50:902–908
   PubMed Web of Science ®Google Scholar
• Vynckier AK, Dierickx L, Voorspoels J, et al. Hot-melt co-extrusion: requirements, challenges and opportunities for pharmaceutical applications. J Pharm Pharmacol 2014;66:167–179
   PubMed Web of Science ®Google Scholar
• Li Y, Pang H, Guo Z, et al. Interactions between drugs and polymers influencing hot melt extrusion. J Pharm Pharmacol 2014;66:148–166
   PubMed Web of Science ®Google Scholar
• Lu M, Guo Z, Li Y, et al. Application of hot melt extrusion for poorly water-soluble drugs: limitations, advances and future prospects. Curr Pharm Des 2014;20:369–387
   PubMed Web of Science ®Google Scholar
• Yang H, Teng F, Wang P, et al. Investigation of a nanosuspension stabilized by Soluplus(R) to improve bioavailability. Int J Pharm 2014;477:88–95
   PubMed Web of Science ®Google Scholar
• Pang S, Ma C, Zhang N, He L. Investigation of the solubility enhancement mechanism of rebaudioside D using a solid dispersion technique with potassium sorbate as a carrier. Food Chem 2015;174:564–570
   PubMed Web of Science ®Google Scholar
• Ramadhani N, Shabir M, McConville C. Preparation and characterisation of Kolliphor(R) P 188 and P 237 solid dispersion oral tablets containing the poorly water soluble drug disulfiram. Int J Pharm 2014;475:514–522
   PubMed Web of Science ®Google Scholar
• Hwang Du H, Kim YI, Cho KH, et al. A novel solid dispersion system for natural product-loaded medicine: silymarin-loaded solid dispersion with enhanced oral bioavailability and hepatoprotective activity. J Microencapsul 2014;31:619–626
   PubMed Web of Science ®Google Scholar
• Bhatnagar P, Dhote V, Mahajan SC, et al. Solid dispersion in pharmaceutical drug development: from basics to clinical applications. Curr Drug Deliv 2014;11:155–171
   PubMed Web of Science ®Google Scholar
• Jahan R, Islam MS, Tanwir A, Chowdhury JA. In vitro dissolution study of atorvastatin binary solid dispersion. J Adv Pharm Technol Res 2013;4:18–24
   PubMedGoogle Scholar
• Dhawan S, Kapil R, Singh B. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol 2011;63:342–351
   PubMed Web of Science ®Google Scholar
• Singh B, Pahuja S, Kapil R, Ahuja N. Formulation development of oral controlled release tablets of hydralazine: optimization of drug release and bioadhesive characteristics. Acta Pharm 2009;59:1–13
   PubMed Web of Science ®Google Scholar
• Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic “design of experiments”. Part I: fundamental aspects. Crit Rev Ther Drug Carrier Syst 2005;22:27–105
   PubMed Web of Science ®Google Scholar
• Kapil R, Dhawan S, Beg S, Singh B. Buccoadhesive films for once-a-day administration of rivastigmine: systematic formulation development and pharmacokinetic evaluation. Drug Dev Ind Pharm 2013;39:466–480
   PubMed Web of Science ®Google Scholar
• Singh B, Rani A, Babita, et al. Formulation optimization of hydrodynamically balanced oral controlled release bioadhesive tablets of tramadol hydrochloride. Sci Pharm 2010;78:303–323
   PubMedGoogle Scholar
• Bussemer T, Peppas NA, Bodmeier R. Evaluation of the swelling, hydration and rupturing properties of the swelling layer of a rupturable pulsatile drug delivery system. Eur J Pharm Biopharm 2003;56:261–270
   PubMed Web of Science ®Google Scholar
• Hong J, Shah JC, McGonagle MD. Effect of cyclodextrin derivation and amorphous state of complex on accelerated degradation of ziprasidone. J Pharm Sci 2011;100:2703–2716
   PubMed Web of Science ®Google Scholar